A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)

The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.

Study Overview

• Status: Completed
• Conditions: Relapsed Solid Tumor; Refractory Solid Tumor
• Intervention / Treatment: Drug: Temozolomide; Drug: Abemaciclib; Drug: Irinotecan; Drug: Dinutuximab; Drug: GM-CSF

• Study Type: Interventional
• Enrollment (Actual): 47
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Australia
  • Western Australia
    • Perth, Western Australia, Australia, 6009
      • Perth Children's Hospital
• Belgium
  • Oost-Vlaanderen
    • Ghent, Oost-Vlaanderen, Belgium, 9000
      • UZ Gent
• France
  • Paris, France, 75248
    • Institut Curie
  • Rhône
    • Lyon, Rhône, France, 69373 CEDEX 08
      • Centre léon bérard
  • Val-de-Marne
    • Villejuif, Val-de-Marne, France, 94800
      • Gustave Roussy
• Germany
  • Berlin, Germany, 13353
    • Charité Campus Virchow-Klinikum
  • Baden-Wurttemberg
    • Heidelberg, Baden-Wurttemberg, Germany, 69120
      • Universitaetsklinikum Heidelberg
  • North Rhine-Westphalia
    • Essen, North Rhine-Westphalia, Germany, 45122
      • Universitaetsklinikum Essen
• Italy
  • Lazio
    • Rome, Lazio, Italy, 168
      • Fondazione Policlinico Universitario Agostino Gemelli
• Japan
  • Tokyo
    • Chuo Ku, Tokyo, Japan, 104-0045
      • National Cancer Center Hospital
• Spain
  • Valencia, Spain, 46026
    • Hospital Universitari i Politecnic La Fe
  • Barcelona [Barcelona]
    • Barcelona, Barcelona [Barcelona], Spain, 8035
      • Hospital Universitari Vall d'Hebron
  • Madrid, Comunidad de
    • Madrid, Madrid, Comunidad de, Spain, 28009
      • Hospital Infantil Universitario Nino Jesus
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85016
      • Phoenix Children's Hospital
  • California
    • Los Angeles, California, United States, 90095-1752
      • The Regents of the University of California - Los Angeles (UCLA Pediatrics)
    • Oakland, California, United States, 94611
      • Kaiser Permanente Oakland
    • Roseville, California, United States, 95661
      • Kaiser Permanente Roseville
    • Santa Clara, California, United States, 95051
      • Kaiser Permanente Santa Clara
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Riley Hospital for Children at Indiana University Health
  • Michigan
    • Grand Rapids, Michigan, United States, 49503
      • Spectrum Health
  • New York
    • New Hyde Park, New York, United States, 11040
      • Cohen Children's Medical Center
  • North Carolina
    • Charlotte, North Carolina, United States, 28203
      • Atrium Health - Carolinas Medical Center
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Cincinnati Children's Hospital Medical Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Children's Hospital of Philadelphia (CHOP)
  • Rhode Island
    • Providence, Rhode Island, United States, 02906
      • Lifespan Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 21 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Parts A and B only:

  • Participants must be less than or equal to (≤)18 years of age.
  • Body weight greater than or equal to (≥)10 kilograms and body surface area (BSA) ≥0.5
  • Participants with any relapsed/refractory malignant solid tumor (excluding lymphoma), including central nervous system tumors, that have progressed on standard therapies.
  • For sites that are actively enrolling Parts B and C, participants with neuroblastoma who are eligible for Part C will be excluded from Part B unless approved by Lilly CRP/CRS.

• Part C only:

  • Participants must be less than (<) 21 years of age.
  • Participants have a BSA ≥0.2 m².
  • Participants with first relapse/refractory neuroblastoma.

• All Parts

  • Participants must have measurable or evaluable disease by RECIST v1.1 or RANO.
  • A Lansky score ≥50 for participants <16 years of age or Karnofsky score ≥50 for participants ≥16 years of age.
  • Participants must have discontinued all previous treatments for cancer or investigational agents and must have recovered from the acute effects to Grade ≤1 at the time of enrollment.
  • Able to swallow and/or have a gastric/nasogastric tube.
  • Adequate hematologic and organ function ≤2 weeks (14 days) prior to first dose of study drug.
  • Females of reproductive potential must have negative urine or serum pregnancy test at baseline (within 7 days prior to starting treatment).
  • Female participants of reproductive potential must agree to use highly effective contraceptive precautions during the trial. For abemaciclib, females should use contraception for at least 3 weeks following the last abemaciclib. For other study drugs, highly effective contraceptive precautions (and avoiding sperm donation) must be used according to their label.
  • Life expectancy of at least 8 weeks and able to complete at least 1 cycle of treatment.
  • Caregivers and participants willing to make themselves available for the duration of the trial.

Exclusion Criteria:

• Received allogenic bone marrow or solid organ transplant.
• Received live vaccination.
• Intolerability or hypersensitivity to any of the study treatments or its components.
• Diagnosed and/or treated additional malignancy within 3 years prior to enrollment that may affect the interpretation of results, with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected in situ cervical and/or breast cancers.
• Pregnant or breastfeeding.
• Active systemic infections.
• Serious and/or uncontrolled preexisting medical condition(s) that would preclude participation in this study.
• Parts A and C only: Have a bowel obstruction.
• Prior treatment with drugs known to be strong inhibitors or inducers of isoenzyme cytochrome P450 3A (CYP3A) or strong inhibitors of uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) if the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.
• Received prior treatment with cyclin-dependent kinase (CDK) 4 & 6 inhibitor.
• Part C only: Received prior systemic therapy for relapsed/refractory neuroblastoma.
• Part C only, have received prior anti-GD2 therapy during induction phase.
• Currently enrolled in any other clinical study involving an investigational product or non-approved use of a drug or device.
• Has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part A Cohort A1; Participants received: Abemaciclib: 70 mg/m², administered orally twice daily (BID).; Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.; Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.	Drug: Temozolomide; Administered orally; Drug: Abemaciclib; Administered orally; Other Names: LY2835219; Drug: Irinotecan; Administered IV
Experimental: Part A Cohort A-1; Participants received: Abemaciclib: 55 mg/m², administered orally BID.; Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.; Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.	Drug: Temozolomide; Administered orally; Drug: Abemaciclib; Administered orally; Other Names: LY2835219; Drug: Irinotecan; Administered IV
Experimental: Part B Cohort B1; Participants received: Abemaciclib: 70 mg/m², administered orally BID.; Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.	Drug: Temozolomide; Administered orally; Drug: Abemaciclib; Administered orally; Other Names: LY2835219
Experimental: Part B Cohort B2; Participants received: Abemaciclib: 90 mg/m², administered orally BID.; Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.	Drug: Temozolomide; Administered orally; Drug: Abemaciclib; Administered orally; Other Names: LY2835219
Experimental: Part B Cohort B3; Participants received: Abemaciclib: 115 mg/m², administered orally BID.; Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.	Drug: Temozolomide; Administered orally; Drug: Abemaciclib; Administered orally; Other Names: LY2835219
Experimental: Part B Cohort B5; Participants received: Abemaciclib: 115 mg/m², administered orally BID.; Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.	Drug: Temozolomide; Administered orally; Drug: Abemaciclib; Administered orally; Other Names: LY2835219
Experimental: Part C Cohort C1; Participants received: Abemaciclib: 55 mg/m², administered orally BID.; Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.; Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.; Dinutuximab: 17.5mg/m²/day, administered IV on Days 2-5 of each cycle.; Granulocyte-macrophage colony-stimulating factor (GM-CSF): 250 μg/m²/day, administered subcutaneously (SC) on Days 6-12 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.	Drug: Temozolomide; Administered orally; Drug: Abemaciclib; Administered orally; Other Names: LY2835219; Drug: Irinotecan; Administered IV; Drug: Dinutuximab; Administered IV; Drug: GM-CSF; Administered SC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)	The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 50 mg/m²/day irinotecan and 100 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.	Cycles 1 and 2 (21 Day Cycles)
Number or Participants With Dose Limiting Toxicities (DLTs) in Part A	DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: Any non-hematologic Grade (G) ≥3 toxicity, except:G3 diarrhea lasting <72 hour (h)Acute irinotecan-associated diarrhea lasting <7 daysG≥3 nausea, vomiting, constipation that lasts <72 hG3 mucositis/stomatitis lasting <72 hG3 fever/infectionG≥3 electrolyte abnormality that lasts <72 h, is not complicated, and resolves spontaneously or responds to conventional medication;G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; orAST/ALT elevation resolving to eligibility criteria within 7 days;; Hematologic toxicities considered a DLT:A >14-day Cycle 2 delay due to neutropenia/thrombocytopeniaG≥3 thrombocytopenia with significant bleeding; orG≥ 4 neutropenic fever	Cycle 1 (21 Day Cycle)
Maximum Tolerated Dose (MTD) of Abemaciclib in Part A	The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.	Cycle 1 (21 Days)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC0-tlast) of Abemaciclib in Part A	PK: (AUC0-tlast) was reported.	Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
PK: (AUC0-tlast) of Irinotecan in Part A	PK: AUC0-tlast) was reported.	2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
PK: (AUC0-tlast) of Temozolomide in Part A	PK: AUC0-tlast was reported.	1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
RP2D of Abemaciclib in Combination With Temozolomide (Part B)	The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 150 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.	Cycles 1 and 2 (21 Day Cycles)
Number or Participants With DLTs in Part B	A DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: Any non-hematologic Grade (G) ≥3 toxicity, except:G3 diarrhea lasting <72 hrAcute irinotecan-associated diarrhea lasting <7 daysG≥3 nausea, vomiting, constipation that lasts <72 hrG3 mucositis/stomatitis lasting <72 hrG3 fever/infectionG≥3 electrolyte abnormality that lasts <72 hr, is not complicated, and resolves spontaneously or responds to conventional medication;G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; orAST/ALT elevation resolving to eligibility criteria within 7 days;; Hematologic toxicities considered a DLT:A >14-day Cycle 2 delay due to neutropenia/thrombocytopeniaG≥3 thrombocytopenia with significant bleeding; orG≥ 4 neutropenic fever	Cycle 1 (21 Day Cycle)
MTD of Abemaciclib in Part B	The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.	Cycle 1 (21 Days)
PK: AUC0-tlast of Abemaciclib in Part B	PK: AUC0-tlast was reported.	Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
PK: AUC0-tlast of Temozolomide in Part B	PK: AUC0-tlast was reported.	1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
Number of Participants With Overall Response Rate (ORR) in Part C.	ORR: Number of participants with best response of Complete Response (CR), Partial Response (PR), or Minor Response (MR) per International Neuroblastoma Response Criteria (INRC).; CR is defined as complete response in all response components:Primary Tumor: <10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumorsSoft tissue and bone metastatic response: nonprimary target and nontarget lesions <10 mm and nodes identified as targets decreased to short axis <10mm and MIBG-avid update of nonprimary lesions completely resolvedBone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions;; PR is defined as PR in >1component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD).; MR is defined PR or CR in >1 component and SD in >1 component and no component with PD	Date of first dose to disease progression or death (Up to 25 Months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Overall Response Rate (ORR): Part A	ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors.; CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).; PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and >50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).	Date of first dose to disease progression or death (Up to 25 Months)
Percentage of Participants With ORR: Part B	ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors.; CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).; PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and >50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).	Date of first dose to disease progression or death (Up to 25 Months)
Duration of Response (DoR): Parts A and B.	DoR is the time between first evidence of CR or PR and disease progression or death due to any cause. RECIST was used for solid tumors and RANO was used for brain tumors.; CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).; PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and >50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).	Date of first evidence of a CR or PR to date of objective disease progression or death due to any cause (Up to 25 Months)
Duration of Response (DoR): Part C	DoR is the time between first evidence of CR, PR or MR and disease progression or death due to any cause. CR, PR, and MR was as per International Neuroblastoma Response Criteria (INRC). - CR is defined as complete response in all response components: Primary Tumor: <10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors Soft tissue and bone metastatic response: nonprimary target and nontarget lesions <10 mm and nodes identified as targets decreased to short axis <10mm and MIBG-avid update of nonprimary lesions completely resolved Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; PR is defined as PR in >1 component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD).; MR is defined PR or CR in >1 component and SD in >1 component and no component with PD	Date of first evidence of a CR, PR, or MR to date of objective disease progression or death due to any cause (Up to 25 Months)
Percentage of Participants With Clinical Benefit Rate (CBR): Part A	The CBR is the percentage of participants with a best response of CR or PR, or Stable Disease (SD) for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors.; CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).; PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and >50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).; SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.	Date of first dose to disease progression or death due to any cause (Up to 25 Months)
Percentage of Participants With CBR: Part B	The CBR is the percentage of participants with a best response of CR or PR, or SD for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors.; CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).; PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and >50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).; SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.	Date of first dose to disease progression or death due to any cause (Up to 25 Months)
Percentage of Participants With Disease Control Rate (DCR): Part A	DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors.; CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).; PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and >50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).; SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.	Date of first dose to measured progressive disease (Up to 25 Months)
Percentage of Participants With DCR: Part B	DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors.; CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO).; PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and >50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).; SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.	Date of first dose to measured progressive disease (Up to 25 Months)
Progression-Free Survival (PFS): Part C	Progression-free survival is measured as the time from first dose of study drug to progressive disease or death, whichever occurs first. PFS for Part C was reported.	Date of first dose to progressive disease or death (Up to 25 Months)
Abemaciclib Tablet Acceptability	Participants were evaluated for abemaciclib acceptability (palatability and ease of administration) by asking a question - " Was it easy or difficult for the study subject to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: Very difficult, difficult, neither easy nor difficult, easy, or very easy.	Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (21 Day Cycles)

Collaborators and Investigators

• Sponsor: Eli Lilly and Company
• Investigators: Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications and helpful links

Helpful Links

• A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors

Study record dates

Study Major Dates

• Study Start (Actual): November 9, 2020
• Primary Completion (Actual): March 15, 2024
• Study Completion (Actual): August 19, 2025

Study Registration Dates

• First Submitted: January 22, 2020
• First Submitted That Met QC Criteria: January 22, 2020
• First Posted (Actual): January 23, 2020

Study Record Updates

• Last Update Posted (Actual): March 2, 2026
• Last Update Submitted That Met QC Criteria: February 8, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Brain tumor; Medulloblastoma; Ependymoma; Solid tumor; Glioblastoma; Rhabdomyosarcoma; Osteosarcoma; Neuroblastoma; Ewing's sarcoma; CDK4; CDK6; Malignant rhabdoid tumor; Malignant glioma; Diffuse intrinsic pontine glioma; High-grade glioma; Recurrent neuroblastoma
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Astrocytoma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Nervous System Neoplasms; Sarcoma; Neoplasms, Connective and Soft Tissue; Neuroectodermal Tumors, Primitive, Peripheral; Neuroectodermal Tumors, Primitive; Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Central Nervous System Neoplasms; Neoplasms, Muscle Tissue; Neoplasms, Complex and Mixed; Myosarcoma; Brain Stem Neoplasms; Infratentorial Neoplasms; Diffuse Intrinsic Pontine Glioma; Glioblastoma; Glioma; Neuroblastoma; Sarcoma, Ewing; Brain Neoplasms; Rhabdomyosarcoma; Osteosarcoma; Ependymoma; Medulloblastoma; Rhabdoid Tumor; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Azoles; Biological Factors; Carbohydrates; Camptothecin; Alkaloids; Dacarbazine; Triazenes; Imidazoles; Intercellular Signaling Peptides and Proteins; Glycoproteins; Glycoconjugates; Colony-Stimulating Factors; Hematopoietic Cell Growth Factors; Cytokines; Temozolomide; Irinotecan; abemaciclib; dinutuximab; Granulocyte-Macrophage Colony-Stimulating Factor
• Other Study ID Numbers: 16950 (H. Lee Moffitt Cancer Center); I3Y-MC-JPCS (Other Identifier: Eli Lilly and Company); 2019-002931-27 (EudraCT Number); 2023-506778-11-00 (Other Identifier: EU Trial Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
• IPD Sharing Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
• IPD Sharing Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No